NASDAQ · TIL
Instil Bio, Inc.
$7.13 -$0.07 (-0.97%) 1D Market open
Instil Bio, Inc.
Key Metrics
$48.83M
Market cap
—
P/E · TTM
—
Revenue · TTM
−$47.38M
Net income
EPS · TTM
$-7.25
Dividend yield
—
Free cash flow
—
Beta · 1Y
1.38
EBITDA · TTM
−$47.77M
Gross margin
—
Snapshot
Market cap$48.83M
Enterprise value—
Shares outstanding6.8M
52-wk range$5.67 – $33.83
Avg volume · 20D71.1K
Net cash
—
Book value / share$16.95
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Instil Bio, Inc.
IPO dateMar 19, 2021
Employees17
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
-33.8% · —
Financial Health
Current ratio39.87
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$183.58M
Cash Flow · TTM
Operating CF
−$33.76M
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
2 / 9
Weak fundamentals · 2 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings